News

Leisure-time physical activity is associated with a lower risk for many types of cancer, including a 17 percent lower risk for myeloma. These key findings were independent of…

Newton, Massachusetts-based Karyopharm Therapeutics has published the results from its Phase 1 trial of selinexor (KPT-330) in patients with advanced solid tumors in the…

Three organizations — CURE Media Group, Multiple Myeloma Research Foundation (MMRF) and Takeda Oncology — joined together in the Moving Mountains for Multiple…

Bristol-Myers Squibb (BMS) Company and AbbVie have announced that the European Commission (EC) has approved Empliciti™ (elotuzumab) for the treatment of multiple…

The Institute for Clinical and Economic Review (ICER), an independent nonprofit based in Boston that analyzes the value of drugs and other medical services, has released a…

Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib), combined with lenalidomide and dexamethasone as a therapeutic approach for relapsed and/or refractory multiple myeloma (MM), markedly…

Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma,…

A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according…

A new class of drugs that activate a protein in cells’ endoplasmic reticulum may be used as an adjuvant therapy to treat B-cell malignancies, according to the…

Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of…